Antibody formulations

A method of administering subcutaneously a formulation, wherein the formulation is within an article of manufacture comprising the formulation and a subcutaneous administration device;

• wherein the formulation comprises an anti-IL13 antibody, wherein the concentration of the anti-IL-13 antibody in the formulation is at least 100 mg/mL and the viscosity of the formulation is less than 15 centipoise (cP) at 25° C., wherein the formulation comprises a histidine acetate buffer, pH 5.4 to 6.0, and the histidine acetate concentration in the buffer is between 5 mM and 40 mM, and wherein the anti-IL-13 antibody is an IgG4 antibody and comprises three heavy chain CDRs, CDR-H1 having the amino acid sequence of SEQ ID NO:
• 1, CDR-H2 having the amino acid sequence of SEQ ID NO:
• 2, and CDR-H3 having the amino acid sequence of SEQ ID NO:
• 3, and three light chain CDRs, CDR-L1 having the amino acid sequence of SEQ ID NO:
• 4, CDR-L2 having the amino acid sequence of SEQ ID NO:
• 5, and CDR-L3 having the amino acid sequence of SEQ ID NO:
• 6.